Navigation Links
Aerovance Appoints Babatunde A. Otulana, M.D., as Chief Medical Officer

BERKELEY, Calif., Feb. 9 /PRNewswire/ -- Aerovance Inc. today announced the appointment of Babatunde A. Otulana, M.D., to the position of senior vice president and chief medical officer.

Dr. Otulana, 52, will provide medical as well as organizational and regulatory leadership to the company as it moves forward with the development of AerovantTM for uncontrolled asthma and AerodermTM for severe atopic eczema. He has more than 20 years of experience in pulmonary research and product development.

"Tunde has a wealth of experience in the planning and implementation of clinical development programs for pulmonary drugs," said Mark Perry, Aerovance's president and chief executive officer. "He will focus on advancing Aerovant through clinical development, beginning with our upcoming Phase IIb clinical trial in patients living with uncontrolled asthma, while further developing Aerovance's pipeline."

Prior to joining the company, Dr. Otulana worked with Aradigm Corp., where he most recently served as senior vice president, development, and chief medical officer. At Aradigm, his responsibilities included the management of all clinical development, regulatory affairs, QA & QC, and R&D activities for respiratory specialty pharmaceutical products. Prior to Aradigm, he was a medical reviewer and team leader at the Division of Pulmonary Drug Products Center for the Drug Evaluation & Research of the U.S. Food and Drug Administration (FDA). Dr. Otulana is a practicing pulmonologist and has published numerous articles in peer-reviewed journals, most recently in the field of pulmonary delivery of therapeutics.

"I am excited to be joining the Aerovance team as the company advances its unique pipeline to meet significant unmet medical needs in the field of allergy and pulmonary medicine," said Dr. Otulana. "Aerovant and Aeroderm represent a new class of compounds which, if successful in development, will provide new tools for physicians in the management of intractable severe asthma and atopic dermatitis respectively, in millions of patients."

Aerovant is a recombinant human IL-4 variant that is a potent inhibitor of IL-4R alpha, a shared component of both the IL-4 and IL-13 receptors. Aerovance acquired the worldwide rights to the drug candidate when the company was formed as a spin-out of Bayer Pharmaceuticals Corporation in 2004.

Aerovance Inc. is a Berkeley, Calif.-based biopharmaceutical company focused on the development and commercialization of breakthrough therapies for the treatment of respiratory and inflammatory diseases. For more information, visit

Editor's Note: Photograph available on request

    Contact:    Andreas Marathovouniotis or David Schull
    Russo Partners
                212-845-4235 or 212-845-4271

                Dave Happel
                Aerovance Inc.

SOURCE Aerovance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Aerovance Secures $20 Million in Debt Financing
2. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
3. January 2009 - Rahu Appoints David Greensmith to Non Executive Directo
4. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
5. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
6. Qforma Appoints Two New Executives
7. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
8. PAREXEL Appoints Josephine Hoppe to Chief Information Officer
9. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
10. Cumberland Pharmaceuticals Appoints Lee Product Director
11. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity ... intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers at ... result of a collaboration among several companies with expertise in toolholding, cutting tools, ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
(Date:6/2/2016)... , June 2, 2016 Perimeter ... Platforms, Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... market will generate revenues of $17.98 billion in 2016. ... DVTEL Inc, a leader in software and hardware technologies ...
Breaking Biology News(10 mins):